- Home
- ACRV vs CRBU Comparison
ACRV vs CRBU Comparison
Compare ACRV & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRV
- CRBU
- Stock Information
- Founded
- ACRV 2018
- CRBU 2011
- Country
- ACRV United States
- CRBU United States
- Employees
- ACRV N/A
- CRBU N/A
- Industry
- ACRV Medicinal Chemicals and Botanical Products
- CRBU Medicinal Chemicals and Botanical Products
- Sector
- ACRV Health Care
- CRBU Health Care
- Exchange
- ACRV Nasdaq
- CRBU Nasdaq
- Market Cap
- ACRV 189.0M
- CRBU 151.2M
- IPO Year
- ACRV 2022
- CRBU 2021
- Fundamental
- Price
- ACRV $5.54
- CRBU $1.31
- Analyst Decision
- ACRV Strong Buy
- CRBU Strong Buy
- Analyst Count
- ACRV 6
- CRBU 5
- Target Price
- ACRV $22.40
- CRBU $11.80
- AVG Volume (30 Days)
- ACRV 69.3K
- CRBU 1.3M
- Earning Date
- ACRV 03-27-2025
- CRBU 03-10-2025
- Dividend Yield
- ACRV N/A
- CRBU N/A
- EPS Growth
- ACRV N/A
- CRBU N/A
- EPS
- ACRV N/A
- CRBU N/A
- Revenue
- ACRV N/A
- CRBU $11,475,000.00
- Revenue This Year
- ACRV N/A
- CRBU N/A
- Revenue Next Year
- ACRV N/A
- CRBU N/A
- P/E Ratio
- ACRV N/A
- CRBU N/A
- Revenue Growth
- ACRV N/A
- CRBU N/A
- 52 Week Low
- ACRV $3.83
- CRBU $1.22
- 52 Week High
- ACRV $11.90
- CRBU $8.33
- Technical
- Relative Strength Index (RSI)
- ACRV 47.59
- CRBU 39.05
- Support Level
- ACRV $5.00
- CRBU $1.30
- Resistance Level
- ACRV $6.08
- CRBU $1.46
- Average True Range (ATR)
- ACRV 0.64
- CRBU 0.09
- MACD
- ACRV 0.01
- CRBU 0.02
- Stochastic Oscillator
- ACRV 25.68
- CRBU 33.33
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.